Investors initially flocked to Moderna (NASDAQ: MRNA) for its highly sought-after coronavirus vaccine, which rapidly transformed the company from a clinical-stage biotech to a profitable commercial entity. However, recent declines in vaccine sales and underwhelming performance of its RSV vaccine have caused the stock to stumble, despite a recent 30% increase over the past month driven by cost-cutting measures and a refocused pipeline. For those seeking a more reliable biotech investment, there are better options than Moderna.
